AF10 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-3696R-Cy5.5 |
| Product Name | AF10 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
FCM
|
| Reactivity | Human, Rat |
| Predicted Reactivity | Mouse, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human AF10/MLLT10 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 8028 |
| Subcellular location | Nucleus |
| Synonyms | AF 10; AF10; AF10_HUMAN; ALL 1 fused gene from chromosome 10; ALL1 fused gene from chromosome 10; ALL1-fused gene from chromosome 10 protein; MLLT 10; MLLT10; Myeloid/lymphoid or mixed lineage leukemia trithorax homolog Drosophila translocated to 10; Myeloid/lymphoid or mixed lineage leukemia translocated to 10; Protein AF 10; Protein AF-10; Protein AF10; Type I AF10 protein. |
| Background | A chromosomal aberration involving MLLT10 is associated with acute leukemias. Translocation t(10;11)(p12;q23) with MLL/HRX. The result is a rogue activator protein.A chromosomal aberration involving MLLT10 is associated with diffuse histiocytic lymphomas. Translocation t(10;11)(p13;q14) with PICALM. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |